These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

934 related articles for article (PubMed ID: 35052763)

  • 21. The Role of Probiotics in Nonalcoholic Fatty Liver Disease: A New Insight into Therapeutic Strategies.
    Meroni M; Longo M; Dongiovanni P
    Nutrients; 2019 Nov; 11(11):. PubMed ID: 31689910
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The Effect of Probiotics (MCP
    Mohamad Nor MH; Ayob N; Mokhtar NM; Raja Ali RA; Tan GC; Wong Z; Shafiee NH; Wong YP; Mustangin M; Nawawi KNM
    Nutrients; 2021 Sep; 13(9):. PubMed ID: 34579068
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Loss of Junctional Adhesion Molecule A Promotes Severe Steatohepatitis in Mice on a Diet High in Saturated Fat, Fructose, and Cholesterol.
    Rahman K; Desai C; Iyer SS; Thorn NE; Kumar P; Liu Y; Smith T; Neish AS; Li H; Tan S; Wu P; Liu X; Yu Y; Farris AB; Nusrat A; Parkos CA; Anania FA
    Gastroenterology; 2016 Oct; 151(4):733-746.e12. PubMed ID: 27342212
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Tea Polyphenol Epigallocatechin Gallate Protects Against Nonalcoholic Fatty Liver Disease and Associated Endotoxemia in Rats via Modulating Gut Microbiota Dysbiosis and Alleviating Intestinal Barrier Dysfunction and Related Inflammation.
    Zuo G; Chen M; Zuo Y; Liu F; Yang Y; Li J; Zhou X; Li M; Huang JA; Liu Z; Lin Y
    J Agric Food Chem; 2024 Apr; ():. PubMed ID: 38607257
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Intestinal Barrier Dysfunction and Gut Microbiota in Non-Alcoholic Fatty Liver Disease: Assessment, Mechanisms, and Therapeutic Considerations.
    Long C; Zhou X; Xia F; Zhou B
    Biology (Basel); 2024 Apr; 13(4):. PubMed ID: 38666855
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Role of microbiota and related metabolites in gastrointestinal tract barrier function in NAFLD.
    Fernandez-Cantos MV; Garcia-Morena D; Iannone V; El-Nezami H; Kolehmainen M; Kuipers OP
    Tissue Barriers; 2021 Jul; 9(3):1879719. PubMed ID: 34280073
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Peroxisome proliferator-activated receptor-alpha activation and dipeptidyl peptidase-4 inhibition target dysbiosis to treat fatty liver in obese mice.
    Silva-Veiga FM; Miranda CS; Vasques-Monteiro IML; Souza-Tavares H; Martins FF; Daleprane JB; Souza-Mello V
    World J Gastroenterol; 2022 May; 28(17):1814-1829. PubMed ID: 35633911
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Negative Effects of a High-Fat Diet on Intestinal Permeability: A Review.
    Rohr MW; Narasimhulu CA; Rudeski-Rohr TA; Parthasarathy S
    Adv Nutr; 2020 Jan; 11(1):77-91. PubMed ID: 31268137
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Small metabolites, possible big changes: a microbiota-centered view of non-alcoholic fatty liver disease.
    Chu H; Duan Y; Yang L; Schnabl B
    Gut; 2019 Feb; 68(2):359-370. PubMed ID: 30171065
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Obesity, fatty liver disease and intestinal microbiota.
    Arslan N
    World J Gastroenterol; 2014 Nov; 20(44):16452-63. PubMed ID: 25469013
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Periodontal treatment and microbiome-targeted therapy in management of periodontitis-related nonalcoholic fatty liver disease with oral and gut dysbiosis.
    Kuraji R; Shiba T; Dong TS; Numabe Y; Kapila YL
    World J Gastroenterol; 2023 Feb; 29(6):967-996. PubMed ID: 36844143
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The Intestinal Barrier and Its Dysfunction in Patients with Metabolic Diseases and Non-Alcoholic Fatty Liver Disease.
    Forlano R; Mullish BH; Roberts LA; Thursz MR; Manousou P
    Int J Mol Sci; 2022 Jan; 23(2):. PubMed ID: 35054847
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Leaky Gut and the Ingredients That Help Treat It: A Review.
    Aleman RS; Moncada M; Aryana KJ
    Molecules; 2023 Jan; 28(2):. PubMed ID: 36677677
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Schisantherin A alleviates non-alcoholic fatty liver disease by restoring intestinal barrier function.
    Yu S; Jiang J; Li Q; Liu X; Wang Z; Yang L; Ding L
    Front Cell Infect Microbiol; 2022; 12():855008. PubMed ID: 36132991
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Interleukin-17 Weakens the NAFLD/NASH Process by Facilitating Intestinal Barrier Restoration Depending on the Gut Microbiota.
    He S; Cui S; Song W; Jiang Y; Chen H; Liao D; Lu X; Li J; Chen X; Peng L
    mBio; 2022 Apr; 13(2):e0368821. PubMed ID: 35266816
    [TBL] [Abstract][Full Text] [Related]  

  • 36. SIRT3 Deficiency Promotes High-Fat Diet-Induced Nonalcoholic Fatty Liver Disease in Correlation with Impaired Intestinal Permeability through Gut Microbial Dysbiosis.
    Chen M; Hui S; Lang H; Zhou M; Zhang Y; Kang C; Zeng X; Zhang Q; Yi L; Mi M
    Mol Nutr Food Res; 2019 Feb; 63(4):e1800612. PubMed ID: 30525304
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Lactobacillus plantarum NA136 ameliorates nonalcoholic fatty liver disease by modulating gut microbiota, improving intestinal barrier integrity, and attenuating inflammation.
    Zhao Z; Chen L; Zhao Y; Wang C; Duan C; Yang G; Niu C; Li S
    Appl Microbiol Biotechnol; 2020 Jun; 104(12):5273-5282. PubMed ID: 32335723
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Contribution of the Intestinal Microbiome and Gut Barrier to Hepatic Disorders.
    Chopyk DM; Grakoui A
    Gastroenterology; 2020 Sep; 159(3):849-863. PubMed ID: 32569766
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Probiotics as a complementary therapeutic approach in nonalcoholic fatty liver disease.
    Ferolla SM; Armiliato GN; Couto CA; Ferrari TC
    World J Hepatol; 2015 Mar; 7(3):559-65. PubMed ID: 25848479
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Colonic permeability is increased in non-cirrhotic patients with nonalcoholic fatty liver disease.
    De Munck TJI; Verhaegh P; Spooren C; Mujagic Z; Wienhold T; Jonkers D; Masclee AAM; Koek GH; Verbeek J
    Dig Liver Dis; 2023 May; 55(5):614-621. PubMed ID: 36710170
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 47.